<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recommended evaluation/initial staging of the patient with mycosis fungoides/Sézary syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recommended evaluation/initial staging of the patient with mycosis fungoides/Sézary syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Recommended evaluation/initial staging of the patient with mycosis fungoides/Sézary syndrome</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Evaluation and staging </td> </tr> <tr> <td class="subtitle2_single">Complete physical examination, including: </td> </tr> <tr> <td class="indent1">Determination of type(s) of skin lesions </td> </tr> <tr> <td class="indent1">Estimate percentage of BSA involved by patches, plaques, and tumor lesions and note any ulceration or folliculocentricity of lesions. The patient's palm (including all fingers) is approximately 1 percent of BSA.* </td> </tr> <tr> <td class="indent1">Identification of any palpable lymph node, especially those ≥1.5 cm in largest diameter or firm, irregular, clustered, or fixed </td> </tr> <tr> <td class="indent1">Identification of any organomegaly </td> </tr> <tr> <td class="subtitle2_single">Skin biopsy </td> </tr> <tr> <td class="indent1">Essential: At least two skin biopsies should be obtained of different anatomic areas and morphology for H&amp;E evaluation. If only one biopsy can be obtained, then the lesion that has the most scaling and induration should be chosen. </td> </tr> <tr> <td class="indent1">If needed: Immunophenotyping to include at least the following markers: CD2, CD3, CD4, CD5, CD7, and CD8, beta-F1 (to confirm alpha-beta TCR), and a B cell marker, such as CD20; CD30 may also be indicated in cases where lymphomatoid papulosis, anaplastic lymphoma, or large-cell transformation is considered.</td> </tr> <tr> <td class="indent1">If needed: Evaluation for clonality of TCR gene rearrangement.</td> </tr> <tr> <td class="subtitle2_single">Blood tests </td> </tr> <tr> <td class="indent1">CBC with manual differential (assess for Sézary cells), comprehensive chemistries, LDH </td> </tr> <tr> <td class="indent1">Analysis for abnormal lymphocytes by either Sézary cell count with determination of the absolute number of Sézary cells and/or flow cytometry (including CD4<sup>+ </sup>/ CD7<sup>-</sup> or CD4<sup>+ </sup>/ CD26<sup>-</sup>)</td> </tr> <tr> <td class="indent1">If needed: TCR gene rearrangement and relatedness to any clone in skin </td> </tr> <tr> <td class="subtitle2_single">Radiologic tests </td> </tr> <tr> <td class="indent1">Radiologic tests are not necessary in patients with T<sub>1</sub>N<sub>0</sub>B<sub>0</sub> or T<sub>2a</sub>N<sub>0</sub>B<sub>0 </sub>stage disease who are otherwise healthy and without complaints directed to a specific organ system. </td> </tr> <tr> <td class="indent1">In all other patients, contrast-enhanced CT scan of chest, abdomen, and pelvis (neck included if clinically indicated) or whole body integrated PET-CT is recommended to further evaluate any potential lymphadenopathy, visceral involvement, or abnormal laboratory tests; in patients unable to safely undergo CT scans, MRI may be substituted. </td> </tr> <tr> <td class="subtitle2_single">Lymph node biopsy </td> </tr> <tr> <td class="indent1">Excisional biopsy is indicated in those patients with a node that is at least 1.5 cm (confirmed by imaging) in diameter; and/or is firm, irregular, clustered, or fixed; and/or significantly PET avid. </td> </tr> <tr> <td class="indent1">Site of biopsy: Preference is given to the largest lymph node draining an involved area of the skin or if FDG-PET scan data are available, the node with highest standardized uptake value. </td> </tr> <tr> <td class="indent1">Analysis: Pathologic assessment by light microscopy, flow cytometry, and TCR gene rearrangement.</td> </tr> </tbody></table></div><div class="graphic_footnotes">BSA: body surface area; TCR: T cell receptor; CBC: complete blood count; LDH: lactate dehydrogenase; CT: computed tomography; PET-CT: positron emission tomography/computed tomography; MRI: magnetic resonance imaging; FDG-PET: <sup>18</sup>F-fluoro-2-deoxyglucose positron emission tomography.<br/>*A more specific BSA calculation can be calculated using the "mSWAT" system: mSWAT = (percent BSA of patches) (1) + (percent BSA of plaques) (2) + (percent BSA of tumor) (4).</div><div class="graphic_reference">Adapted from:<br/><ol>
<li>Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.</li></ol>This table was created using research originally published in Blood. Modified from: Prince HM, Whittaker S, Hoppe RT. How I treat my mycosis fungoides and Sézary syndrome. Blood 2009; 114:4337. Copyright © 2009 American Society of Hematology.</div><div id="graphicVersion">Graphic 75528 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
